Incorporation of fucose into glycans independent of the GDP-fucose transporter SLC35C1 preferentially utilizes salvaged over de novo GDP-fucose.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
08 2022
Historique:
received: 30 12 2021
revised: 22 06 2022
accepted: 23 06 2022
pubmed: 1 7 2022
medline: 9 9 2022
entrez: 30 6 2022
Statut: ppublish

Résumé

Mutations in the SLC35C1 gene encoding the Golgi GDP-fucose transporter are known to cause leukocyte adhesion deficiency II. However, improvement of fucosylation in leukocyte adhesion deficiency II patients treated with exogenous fucose suggests the existence of an SLC35C1-independent route of GDP-fucose transport, which remains a mystery. To investigate this phenomenon, we developed and characterized a human cell-based model deficient in SLC35C1 activity. The resulting cells were cultured in the presence/absence of exogenous fucose and mannose, followed by examination of fucosylation potential and nucleotide sugar levels. We found that cells displayed low but detectable levels of fucosylation in the absence of SLC35C1. Strikingly, we show that defects in fucosylation were almost completely reversed upon treatment with millimolar concentrations of fucose. Furthermore, we show that even if fucose was supplemented at nanomolar concentrations, it was still incorporated into glycans by these knockout cells. We also found that the SLC35C1-independent transport preferentially utilized GDP-fucose from the salvage pathway over the de novo biogenesis pathway as a source of this substrate. Taken together, our results imply that the Golgi systems of GDP-fucose transport discriminate between substrate pools obtained from different metabolic pathways, which suggests a functional connection between nucleotide sugar transporters and nucleotide sugar synthases.

Identifiants

pubmed: 35772493
pii: S0021-9258(22)00648-2
doi: 10.1016/j.jbc.2022.102206
pmc: PMC9304781
pii:
doi:

Substances chimiques

Membrane Transport Proteins 0
Monosaccharide Transport Proteins 0
Polysaccharides 0
SLC35C1 protein, human 0
Guanosine Diphosphate Fucose 15839-70-0
Fucose 28RYY2IV3F

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102206

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Edyta Skurska (E)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland.

Bożena Szulc (B)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland.

Dorota Maszczak-Seneczko (D)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland.

Maciej Wiktor (M)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland.

Wojciech Wiertelak (W)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland.

Aleksandra Makowiecka (A)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland.

Mariusz Olczak (M)

Faculty of Biotechnology, University of Wroclaw, Poland, Wrocław, Poland. Electronic address: mariusz.olczak@uwr.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH